Search
2 articles for “gliptin”
-
Dipeptidyl peptidase-IV (DPP-IV) Inhibitors – a promising oral anti-diabetic drug
Abstract: Dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins i.e glucagon-like peptide1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Incretins augment the insulin release by a blood glucose-dependent mechanism. Generally DPP-IV enzyme is responsible for inactivating incretins and this enzyme inhibition will prolong and enhance the activity of GLP-1 and GIP. DPP-IV inhibitors increase post prandial insulin secretion, decreases glucagon secretion and seems to have beneficial effect on cardiovascular system, …
Published in Research and Reviews: A Journal of Pharmaceutical Science · Vol. 11, Issue 3, 2020 · pp. 1–6 Read article
-
Practical approach for Type 2 Diabetes: Role of DPP4 Inhibitors
Abstract: Dipeptidyl peptidase-4 inhibitors (DPP-4Is) have become essential in managing type 2 diabetes mellitus (T2DM) due to their ability to enhance incretin hormone activity, which promotes insulin secretion and inhibits glucagon release. These agents effectively lower HbA1c levels by 0.5–1.0%, are weight-neutral, and have a low risk of hypoglycemia, making them suitable for a broad patient population, including the elderly. The antidiabetic market in India is vast. Gliptin as group row …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 14, Issue 2, 2024 · pp. 20–26 Read article